Formulations and carrier systems including farnesylthiosalycylic moities

Patent metadata

Field	Value
Publication number	US-9855341-B2
Application number	US-201514625873-A
Country	US
Kind code	B2
Filing date	Feb 19, 2015
Priority date	Feb 19, 2014
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

A method of forming or creating a formulation for a compound to be delivered includes creating a carrier agent by conjugating at least one hydrophobic domain or hydrophobic compound with at least one hydrophilic domain or hydrophilic compound and associating the compound to be delivered with the carrier agent to create the formulation. The at least one hydrophobic compound has the formula:

wherein R1 is a farnesyl group, a geranyl group or geranyl-geranyl group, X is O, S, SO, SO 2 , NH or Se, Z is C—R 2 or N, R 2 is H, CN, CO 2 R 7 , SO 3 R 7 , CONR 7 R 8 or SO 2 NR 7 R 8 , wherein R 7 and R 8 are each independently H, an alkyl group, an alkenyl group, CO 2 M or SO 3 M, wherein M is a cation and R 3 , R 4 , and R 5 are independently H, a carboxyl group, an alkyl group, an alkenyl group, an aminoalkyl group, a nitroalkyl group, a nitro group, a halo atom, an amino group, a mono-alkylamino group, a di-alkylamino group, mercapto group, a mercaptoalkyl group, an azido group or a thiocyanato group. A plurality of the carrier agents are adapted to assemble into a structure. The hydrophobic compound is cleavably conjugated to the at least one hydrophilic compound via a linkage which is labile in vivo.

First claim

What is claimed is:

1. A formulation, comprising:
a carrier agent formed by conjugating at least one biologically active hydrophobic compound selected from the group consisting of S-trans, trans-farnesylthiosalicylic acid, S-trans, trans-farnesylthiosalicylic acid amide (FTS-amide),S-trans, trans-farnesylthiosalicylic acid methylamide (FTS-MA) and S-trans, trans-farnesylthiosalicylic acid dimethylamide (FTS-DMA) with at least one hydrophilic polymer selected from the group consisting of a polyalkylene oxide, a polyvinylalcohol, a polyacrylic acid, a polyacrylamide, a polyoxazoline, a polysaccharide and a polypeptide,
wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, the linkage being selected from the group consisting of an ester linkage, a disulfide linkage, pH-sensitive linkage, ROS-sensitive linkage, or protease-sensitive linkage, and
a biologically active compound associated with the carrier agent.

2. The formulation of claim 1 wherein the at least one hydrophilic polymer is a polyalkylene oxide.

3. The formulation of claim 1 wherein the linkage comprises an ester linkage.

4. The formulation of claim 1 wherein the linkage comprises a disulfide linkage.

5. The formulation of claim 4 wherein the at least one hydrophilic polymer is a polyalkylene oxide.

6. The formulation of claim 5 wherein the polyalkylene oxide is a polyethylene glycol.

7. The formulation of claim 6 wherein the polyethylene glycol has a molecular weight of at least 1 KDa.

8. The formulation of claim 1 wherein the carrier agent provides a loading capacity for the biologically active hydrophobic compound of at least 10%.

9. The formulation of claim 2 wherein the biologically active compound is paclitaxel, doxorubicin, curcumin, bicalutamide, etoposide, camptothecin, a camptothecin analog, pemetrexed, docetaxel, epirubicin, doxorubicin, vinblastine, vindesine, etoposide, hydroxycamptothecin, irinotecan, mitoxantrone, tamoxifen, imatinib, gefitinib, erlotinib, sorafenib, and bortezomib.

10. The formulation of claim 2 wherein the biologically active compound is an anticancer agent.

11. The formulation of claim 2 wherein the carrier agent is formed by conjugating the at least one biologically active hydrophobic compound with at least one compound interactive agent and the at least one hydrophilic compound, the at least one compound interactive agent comprising at least one group that interacts with the biologically active compound.

12. The formulation of claim 11 wherein the at least one compound interactive agent comprises at least one of a fluorenylmethyloxycarbonyl group, a carbobenzyloxy group, an isobutoxycarbamate group, a naphthylacetyl group, a carbazole group, a quinolone group, an isoquinolone group, or a group which is a residue of a molecule selected from the group of the biologically active compound, a portion of the biologically active compound, (9H-fluoren-9-yl)methanamine, (9H-fluoren-9-yl)methanol, 9H-fluoren-9-amine, naphthalene, 1,1′-bi-2-naphthol (BINOL), camptothecin, a camptothecin analog, pemetrexed, docetaxel, paclitaxel, epirubicin, doxorubicin, vinblastine, vindesine, etoposide, hydroxycamptothecin, irinotecan, mitoxantrone, tamoxifen, tretinoin, curcumin, imatinib, gefitinib, erlotinib, sorafenib, and bortezomib, or a derivative thereof.

13. The formulation of claim 11 wherein the at least one compound interactive agent comprises at least one fluorenylmethyloxycarbonyl group or a derivative thereof.

14. The formulation of claim 1 wherein the plurality of the carrier agents are adapted to assemble into micelles.

15. The formulation of claim 14 wherein the average size of the micelles is less than 100 nm.

16. The formulation of claim 14 wherein the average size of the micelles is in the range of 20-30 nm.

17. A method of forming a formulation according to claim 1 comprising:
forming the carrier agent by conjugating the at least one biologically active hydrophobic compound with the at least one hydrophilic compound, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via the linkage which is labile in vivo, and associating a biologically active compound with the carrier agent.

18. A method of delivering a biologically active compound to a patient, comprising:
delivering to the patient a composition comprising a compound according to claim 1 .

19. A composition formed by:
conjugating at least one biologically active hydrophobic compound selected from the group consisting of farnesylthiosalicylic acid, S-trans, trans-farnesylthiosalicylic acid, S-trans, trans-farnesylthiosalicylic acid amide (FTS-amide),S-trans, trans-farnesylthiosalicylic acid methylamide (FTS-MA) and S-trans, trans-farnesylthiosalicylic acid dimethylamide (FTS-DMA) with at least one hydrophilic polymer selected from the group consisting of a polyalkylene oxide, a polyvinylalcohol, a polyacrylic acid, a polyacrylamide, a polyoxazoline, a polysaccharide and a polypeptide via at least one linkage which is cleavable in vivoo, the linkage being selected from the group consisting of an ester linkage, a disulfide linkage, pH-sensitive linkage, ROS-sensitive linkage, or protease-sensitive linkage.

20. The composition of claim 19 wherein the composition is formed by conjugating the at least one biologically active hydrophobic compound with at least one compound interactive agent and the at least one hydrophilic polymer, the at least one compound interactive agent comprising at least one group that interacts with a biologically active compound to be delivered via the composition.

21. The composition of claim 20 wherein the at least one compound interactive agent comprises at least one of a fluorenylmethyloxycarbonyl group, a carbobenzyloxy group, an isobutoxycarbamate group, a naphthylacetyl group, a carbazole group, a quinolone group, an isoquinolone group, or a group which is a residue of a molecule selected from the group of the biologically active compound, a portion of the biologically active compound, (9H-fluoren-9-yl)methanamine, (9H-fluoren-9-yl)methanol, 9H-fluoren-9-amine, naphthalene, 1,1′-bi-2-naphthol (BINOL), camptothecin, a camptothecin analog, pemetrexed, docetaxel, paclitaxel, epirubicin, doxorubicin, vinblastine, vindesine, etoposide, hydroxycamptothecin, irinotecan, mitoxantrone, tamoxifen, tretinoin, curcumin, imatinib, gefitinib, erlotinib, sorafenib, and bortezomib, or a derivative thereof.

22. The composition of claim 21 wherein the at least one compound interactive agent comprises at least one fluorenylmethyloxycarbonyl group or a derivative thereof.

23. The composition of claim 21 wherein a plurality of the compositions are adapted to assemble into a micelle.

24. The composition of claim 21 wherein the at least one linkage comprises an ester linkage.

25. The composition of claim 21 wherein the at least one linkage comprises a disulfide linkage.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Li Song
• Huang Yixian
• Zhang Xiaolan
• Gao Xiang

Classifications

• C08L2203/02

  for biomedical use · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• C08G65/33306

  acyclic · CPC title

• C08G65/334

  containing sulfur · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title